Small and innovative molecules as new strategy to revert MDR

Frontiers in Oncology

Volumn 4 JAN, Issue , 2014, Pages

  Zinzi, Laura ^a   Capparelli, Elena ^a   Cantore, Mariangela ^a   Contino, Marialessandra ^a   Leopoldo, Marcello ^a   Colabufo, Nicola Antonio ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Dual effect; MDR; MDR reverting activity; Multitarget drugs; P gp

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CALCEIN; CARBON 11; CYCLOSPORIN A; DOXORUBICIN; ELACRIDAR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; INDIRUBIN; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN; TARIQUIDAR; TOPOTECAN; VERAPAMIL;

BIOASSAY; CLINICAL TRIAL (TOPIC); DRUG PENETRATION; DRUG SENSITIVITY; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84893637360     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00002     Document Type: Review

References (68)

1. Ross DD, Doyle LA. Mining our ABCs: pharmacogenomic approach for evaluating transporter function in cancer drug resistance. Cancer Cell (2004) 6:105-7. doi: 10.1016/j.ccr.2004.08.003
2. Pharm AN, Penchala S, Graf RA, Wang J, Huang Y. Multidrug Resistance: Biological and Pharmaceutical Advance in the Antitumour Treatment. Kerala: Research Signpost (2008). 19 p.
3. Gimenez-Bonafe P, Guillen Canovas A, Ambrosio S, Tortosa A, Perez-Tomas R. Multidrug Resistance: Biological and Pharmaceutical Advance in the Antitumour Treatment. Kerala: Research Signpost (2008). 63 p.
4. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets (2006) 7:861-79. doi:10.2174/138945006777709593
5. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 2:48-58. doi:10.1038/nrc706
6. Colabufo NA, Berardi F, Contino M, Niso M, Perrone R. ABC pumps and their role in active drug transport. Curr Top Med Chem (2009) 9:119-29. doi:10.2174/156802609787521553
7. German UA. P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J Cancer (1996) 32A:927-44. doi:10.1016/0959-8049(96)00057-3
8. Gottesman MM, Ambudkar SV, Xia D. Structure of a multidrug transporter. Nat Biotechnol (2009) 27:546-7. doi:10.1038/nbt0609-546
9. Avendaño C, Menendez JC. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr. Med Chem (2002) 9:159-93. doi:10.2174/0929867023371175
10. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry (2000) 39:11901-6. doi:10.1021/bi000559b
11. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al. Structure of P-glycoprotein reveals a molecular basis for polyspecific drug binding. Science (2009) 323:1718-22. doi:10.1126/science.1168750
12. Callaghan R, Ford RC, Kerr ID. The translocation mechanism of P-glycoprotein. FEBS Lett (2006) 580:1056-63. doi:10.1016/j.febslet.2005.11.083
13. Constantinides PP, Wasan KM. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci (2007) 96:235-48. doi:10.1002/jps.20780
14. vanVeen HW, Higgins CF, Konings WN. Multidrug transport by ATP binding cassette transporters: a proposed two-cylinder engine mechanism. Res Microbiol (2001) 152:365-74. doi:10.1016/S0923-2508(01)01208-6
15. Sharom FJ, Siarheyeva A. Multidrug Resistance: Biological and Pharmaceutical Advance in the Antitumour Treatment. Kerala: Research Signpost (2008). 261 p.
16. Colabufo NA, Berardi F, Perrone MG, Capparelli E, Cantore M, Inglese C, et al. Substrates, inhibitors and activators of P-glycoprotein: candidates for radiolabeling and imaging perspectives. Curr Top Med Chem (2010) 10:1703-14. doi:10.2174/156802610792928022
17. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos (2008) 36:268-75. doi:10.1124/dmd.107.017434
18. Arellano C, Philibert C, Vachoux C, Woodley J, Houin G. The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs. J Pharm Pharm Sci (2007) 10:26-36.
19. Berruet N, Sentenac S, Auchere D, Gimenez F, Farinotti R, Fernandez C. Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats. J Pharm Pharm Sci (2005) 8:226-34.
20. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm (2004) 277:3-9. doi:10.1016/j.ijpharm.2002.12.002
21. Cano-Gauci DF, Riordan JR. Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation. Biochem Pharmacol (1987) 36:2115-23. doi:10.1016/0006-2952(87)90139-0
22. Teodori E, Dei S, Martelli C, Scapecchi S, Gualtieri F. Multidrug Resistance: Biological and Pharmaceutical Advance in the Antitumour Treatment. Kerala: Research Signpost (2008). 141 p.
23. Luurtsema G, Molthoff CF, Schuit RC, Windhorst AD, Lammertsma AA, Franssen EJ. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl Med Biol (2005) 32(1):87-93. doi:10.1016/j.nucmedbio.2004.06.007
24. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther (2000) 293:376-82.
25. Zoghbi SS, Liow JS, Yasuno F, Hong J, Tuan E, Lazarova N, et al. 11C-loperamide and its N-desmethylradiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med (2008) 49:649-56. doi:10.2967/jnumed.107.047308
26. Kreisl WC, Liow JS, Kimura N, Seneca N, Zoghbi SS, Morse CL, et al. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med (2010) 51:559-66. doi:10.2967/jnumed.109.070151
27. Muzi M, Mankoff DA, Link JM, Shoner S, Collier AC, Sasongko L, et al. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J Nucl Med (2009) 50:1267-75. doi:10.2967/jnumed.108.059162
28. Ishiwata K, Kawamura K, Yanai K, Hendrikse NH. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med (2007) 48:81-7.
29. Syvänen S, Blomquist G, Sprycha M, Höglund AU, Roman M, Eriksson O, et al. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage (2006) 32:1134-41. doi:10.1016/j.neuroimage.2006.05.047
30. Syvänen S, Hooker A, Rahman O, Wilking H, Blomquist G, Långström B, et al. Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. J Pharm Sci (2008) 97:5386-400. doi:10.1002/jps.21359
31. Planting AS, Sonneveld P, van der Gaast A, Sparreboom A, van der Burg ME, Luyten GP, et al. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol (2005) 55:91-9. doi:10.1007/s00280-004-0905-z
32. De Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett (1999) 146:117-26. doi:10.1016/S0304-3835(99)00182-2
33. De Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, van Tellingen O. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res (2007) 13:6440-9. doi:10.1158/1078-0432.CCR-07-1335
34. Dörner B, Kuntner C, Bankstahl JP, Bankstahl M, Stanek J, Wanek T, et al. Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem (2009) 52:6073-82. doi:10.1021/jm900940f
35. Yamasaki T, Kawamura K, Hatori A, Yui J, Yanamoto K, Yoshida Y, et al. PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein. Nucl Med Commun (2010) 31(11):985-93. doi:10.1097/MNM.0b013e32833fbf87
36. Wanek T, Kuntner C, Bankstahl JP, Bankstahl M, Stanek J, Sauberer M, et al. A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. Eur J Nucl Med Mol Imaging (2012) 39:149-59. doi:10.1007/s00259-011-1941-7
37. Stewart AJ, Mistry P, Dangerfield W, Bootle D, Baker M, Kofler B, et al. Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs (2001) 12:359-67. doi:10.1097/00001813-200104000-00009
38. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, et al. In vitro and in vivo reversal of P-glycoprotein mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res (2001) 61:749-58.
39. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res (2000) 6:4186-91.
40. Bankstahl JP, Kuntner C, Abrahim A, Karch R, Stanek J, Wanek T, et al. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med (2008) 49:1328-35. doi:10.2967/jnumed.108.051235
41. Müllauer J, Karch R, Bankstahl JP, Bankstahl M, Stanek J, Wanek T, et al. Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats. Nucl Med Biol (2013) 40:755-63. doi:10.1016/j.nucmedbio.2013.05.005
42. Bauer M, Karch R, Zeitlinger M, Stanek J, Philippe C, Wadsak W, et al. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. J Nucl Med (2013) 54(8):1181-7. doi:10.2967/jnumed.112.118232
43. Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, et al. Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem (2008) 16:362-73. doi:10.1016/j.bmc.2007.09.039
44. Van Waarde A, Ramakrishnan NK, Rybczynska AA, Elsinga PH, Berardi F, de Jong JR, et al. Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and expression. J Med Chem (2009) 52:4524-32. doi:10.1021/jm900485a
45. Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, et al. 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorg Med Chem (2008) 16:3732-43. doi:10.1016/j.bmc.2008.01.055
46. Azzariti A, Quatrale AE, Porcelli L, Colabufo NA, Cantore M, Cassano G, et al. MC70 potentiates doxorubicin efficacy in colon and breastcancer in vitro treatment. Eur J Pharmacol (2011) 670:74-84. doi:10.1016/j.ejphar.2011.08.025
47. Colabufo NA, Berardi F, Perrone MG, Cantore M, Contino M, Inglese C, et al. Multi-drug-resistancereverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors. ChemMedChem (2009) 4:188-95. doi:10.1002/cmdc.200800329
48. Colabufo NA, Contino M, Cantore M, Capparelli E, Perrone MG, Cassano G, et al. Naphthalenyl derivatives for hitting P-gp/MRP1/BCRP transporters. Bio Med Chem (2013) 21:1324-32. doi:10.1016/j.bmc.2012.12.021
49. Wanek T, Kuntner C, Banksthahl JP, Stanek J, Sauberer M, Mairinger S, et al. A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. Eur J Nucl Med Mol Imaging. (2012) 39:149-59. doi:10.1007/s00259-011-1941-7
50. Pellicani RZ, Stefanachi A, Niso M, Carotti A, Leonetti F, Nicolotti O, et al. Potent galloyl-based selective modulators targeting multidrug resistance associated protein 1 and P-glycoprotein. J Med Chem (2012) 55:424-36. doi:10.1021/jm201305y
51. Feelisch M, Schonafinger K, Noack E. Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans. Biochem Pharmacol (1992) 44:1149-57. doi:10.1016/0006-2952(92)90379-W
52. Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, et al. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inibhiting the drug efflux. Cancer Res (2005) 65:516-25.
53. Medana C, Ermondi G, Fruttero R, Di Stilo A, Ferretti C, Gasco A. Furoxans as nitric oxide donors. 4-Phenyl-3-furoxancarbonitrile: thiol-mediated nitric oxide release and biological evaluation. J Med Chem (1994) 37:4412-6. doi:10.1021/jm00051a020
54. Sorba G, Medana C, Fruttero R, Cena C, Di Stilo A, Galli U, et al. Water soluble furoxan derivatives as NO prodrugs. J Med Chem (1997) 40:463-9. doi:10.1021/jm970281u
55. Fruttero R, Crosetti M, Chegaev K, Guglielmo S, Gasco A, Berardi F, et al. Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein. J Med Chem (2010) 53:5467-75. doi:10.1021/jm100066y
56. Mechetner E, Roninson IB. Efficient innhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA (1992) 89:5824-8. doi:10.1073/pnas.89.13.5824
57. Thierry AR, Vige D, Coughlin SS, Belli JA, Dritschillo A, Rahman A. Modulation of doxorubicin resistance in multidrug-resistent cells by liposomes. FASEB J (1993) 7:572-9.
58. Cuvier C, Roblot-treupel L, Millot JM, Lizard G, Chevillard S, Manfait M, et al. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharmacol (1992) 44:509-17.
59. Ferlini C, Distefano M, Pignatelli F, Lin S, Riva A, Bombardelli E, et al. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors. Br J Cancer (2000) 83(12):1762-8. doi:10.1054/bjoc.2000.1500
60. Su Y, Cheng X, Tan Y, Hu Y, Zhou Y, Liu J, et al. Synthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanisms. PLoS One (2012) 7(3):e32782. doi:10.1371/journal.pone.0032782
61. Han C, Huang Z, Zheng C, Wan L, Zhang L, Peng S, et al. Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer. J Med Chem (2013) 56:4738-48. doi:10.1021/jm400463q
62. Sullivan R, Graham CH. Chemosensitization of cancer bynitric oxide. Curr Pharm Des (2008) 14:1113-23. doi:10.2174/138161208784246225
63. Li CM, Wang Z, Lu Y, Ahn S, Narayanan R, Kearbey JD, et al. Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor. Cancer Res (2011) 71:216-24. doi:10.1158/0008-5472.CAN-10-1725
64. Hall MD, Handley MD, Gottesman MM. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci (2009) 30:546-56. doi:10.1016/j.tips.2009.07.003
65. Laberge RM, Ambadipudi R, Georges E. P-glycoprotein (ABCB1) modulates collateral sensitivity of a multidrug resistant cell line to verapamil. Arch Biochem Biophys (2009) 491:53-60. doi:10.1016/j.abb.2009.09.012
66. Niso M, Abate C, Contino M, Ferorelli S, Azzariti A, Perrone R, et al. Sigma-2 receptor agonists as possible antitumor agents in resistant tumors: hints for collateral sensitivity. ChemMedChem (2013) 8:2026-2035. doi:10.1002/cmdc.201300291
67. Bech-Hansen NT, Till JE, Ling V. Pleiotropic phenotype of colchicines resistant CHO cells: cross-resistance and collateral sensitivity. J Cell Physiol (1976) 8:23-31. doi:10.1002/jcp.1040880104
68. Callaghan R, Riordan JR. Collateral sensitivity of multidrug resistant cells to narcotic analgesics is due to effects on the plasma membrane. Biochim Biophys Acta (1995) 1236:155-62. doi:10.1016/0005-2736(95)00042-2